Ładuje się......
Early clinical experience with the novel proteasome inhibitor PS–519
AIMS: The main objective of this study was to investigate the safety, tolerability and pharmacodynamics of the novel proteasome inhibitor PS−519 in young male volunteers. Many pro-inflammatory mediators such as cytokines and cell adhesion molecules that are responsible for the development of the cer...
Zapisane w:
| Główni autorzy: | , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Blackwell Science Inc
2002
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1874419/ https://ncbi.nlm.nih.gov/pubmed/12236847 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.2002.01638.x |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|